Search results :

Erlotinib

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: L01XE03

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11
Anxiety 21% x x x x x
Erythema 18% x
Dyspnoea 4% - 45% 11% - 35% x x x x x x x x x x x
Headache 17% x x x x x x x x x
Diarrhoea 0% - 62% 0% - 18% x x x x x x x x x x x
Fatigue 4% - 73% 4% - 45% x x x x x x x x x x x
Rash 0% - 85% 0% - 17% x x x x x x x x x x x
Dysphagia 12% x
Dyspepsia 12% x x x x x x x x
Weight decreased 12% x x x x x x x x x
Insomnia 12% x x x x x
Anorexia 1% - 52% 1% - 38% x x x x x x x x x x x
Chest pain 0% - 18% x
Arthralgia 1% - 14% x x
Infection 0% - 24% 0% - 15% x x x x x x x x x x x
Cough 0% - 48% 0% - 29% x x x x x x x x x x
Asthenia 3.6% x
Back pain 0% - 19% x
Mucosal inflammation 0% - 18% x
Nausea 0% - 33% 0% - 24% x x x x x x x x x x x
Nail changes postmarketing, 10% x x x x
Abdominal pain 1% - 11% 1% - 7% x x x x x x x x x
Gastrointestinal haemorrhage 2% x x x x x x x x x x x
Vomiting 1% - 23% 0% - 19% x x x x x x x x x x
Musculoskeletal pain 0% - 11% x
Interstitial lung disease 0.6% x x x x x x
Conjunctivitis 0% - 18% 0% - 2% x x x x x x x x x x x
Pruritus 0% - 16% 0% - 5% x x x x x x x x x x x
Stomatitis 0% - 17% 0% - 3% x x x x x x x x x x x
Dry skin 0% - 21% 0% - 4% x x x x x x x x x x x
Connective tissue disorder postmarketing x
Eye disorder postmarketing x x x x x
Hirsutism postmarketing x x x x x x x
Inflammation postmarketing x x
Myopathy postmarketing x
Rhabdomyolysis postmarketing x
Uveitis postmarketing x x x
Unspecified disorder of skin and subcutaneous tissue postmarketing x x x x
Alopecia x x x x x x x
Haemolytic anaemia x x x x x
Arrhythmia x x x x x
Mental disorder x x x
Blister x x
Obliterative bronchiolitis x
Cardiovascular disorder x
Cellulitis x x x
Colitis x x x x x
Constipation x x x x
Ulcerative keratitis x x x x x x x x x
Dehydration x x
Depression x x x x x x x x
Dizziness x x x x
Oedema x x x x
Toxic epidermal necrolysis x x x
Epistaxis x x x x x x x
Body temperature increased x x x x x x x x
Flatulence x x x x x x x
Folliculitis x x x
Gastritis x x x x x
Gastrointestinal disorder x x x x x
Haematemesis x x x x x
Haematochezia x x x x x
Haemorrhage x x x x x x x
Hepatitis x
Hepatorenal syndrome x
Hypokalaemia x x x x
Intestinal perforation x
Ischaemia x x x x x x
Keratitis x x x x x x x x x
Keratoconjunctivitis sicca 0% - 12% 0% - 3% x x x x x x x x x x x
Renal failure acute x x x
Liver disorder x x x x
Lung disorder x
Mediastinal disorder x x x x
Melaena x x x x x
Myocardial infarction x x x x x x
Nail disorder x x
Nephritis x
Nervous system disorder x x x
Neutropenia x x x
Pain x
Pancreatitis x x x x x
Paronychia postmarketing, 0% - 14% x x x x x x x x
Peptic ulcer x x x x x x
Peptic ulcer haemorrhage x x x x x
Pneumonia x x x x x
Proteinuria x
Pulmonary fibrosis x
Renal failure x x
Acute respiratory distress syndrome x
Rosacea x
Skin disorder x x x
Stevens-Johnson syndrome x x x
Cerebrovascular accident x x x x x x
Syncope x x x x x
Thrombocytopenia x x x x x
Urinary tract disorder x
Hepatic failure x x x x x x x
Deep vein thrombosis x x x x x
Gastrointestinal perforation x
Bone pain x x x x
Alanine aminotransferase increased x x x x x x x x x x
Malnutrition x x x x
Skin hyperpigmentation x x x x
Interstitial pneumonia x
Fatal outcomes x x x
Microangiopathic haemolytic anaemia x x x x x
Skin fissures x x x x
Myalgia x x x x
Decreased appetite x
Tenderness x
Dermatitis acneiform x x x
Hepatotoxicity x x
Lung infiltration x
Pancreatic carcinoma x x x x
Skin exfoliation x
Pustule x
Disease progression x x x
Sepsis x x x
Hepatobiliary disease x x x x
Corneal perforation x
Rigors x x x x x x x
Neuropathy x x x x x x x
Metastases to liver x x x x x x x x x x
Drug interaction x x x x
Acne x x x
Infestation NOS x x x x x x x
Lung infection x
Pulmonary toxicity x
Hepatic impairment x
Ileus x x x x x
Renal impairment x x x x x x
Papulopustular rash x x x x
Cerebral haemorrhage x x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

Erlotinib

Side effects:40
Source:BC Cancer

ERLOTINIB

Side effects:64
Source:FDA Structured Product Label

ERLOTINIB HYDROCHLORIDE / TARCEVA

Side effects:60
Source:FDA

ERLOTINIB HYDROCHLORIDE / TARCEVA

Side effects:62
Source:FDA

ERLOTINIB HYDROCHLORIDE / TARCEVA

Side effects:66
Source:FDA

ERLOTINIB

Side effects:69
Source:FDA Structured Product Label

ERLOTINIB HYDROCHLORIDE / TARCEVA

Side effects:22
Source:FDA

ERLOTINIB (ERLOTINIB HYDROCHLORIDE) / TARCEVA

Side effects:39
Source:Health Canada

erlotinib / erlotinib

Side effects:66
Source:EMA

Tarceva / Tarceva, Film coated tablet

Side effects:63
Source:Medsafe

TARCEVA / TARCEVA

Side effects:69
Source:medicines.org.au

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label